Novartis buys Gyroscope Therapeutics for $ 1.5 billion from Reuters

(Reuters) – Healthcare investment firm Syncona Ltd on Wednesday announced that Novartis AG will purchase its Gyroscope Therapeutics unit for up to $ 1.5 billion as the Swiss drug maker seeks access to British society’s gene therapy for a disease causing blindness.

Warning: Fusion media would like to remind you that the data contained in this site is not necessarily real time or accurate. All CFDs (stocks, indices, futures) and Forex prices are not provided by the exchanges but rather by market makers. The prices may therefore not be exact and differ from the actual market price, which means that the prices are indicative and not suitable for trading purposes. Therefore, Fusion Media assumes no responsibility for any business losses that you may incur as a result of the use of such data.

Fusion media or anyone involved with Fusion Media will not accept any responsibility for any loss or damage resulting from reliance on any information, including data, quotes, graphics and buy / sell signals contained in this website. Please be fully informed about the risks and costs associated with trading in the financial markets, it is one of the riskiest forms of investing possible.